Related Experiment Videos
Antiplatelet drugs. A comparative review
1Institut für Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Germany.
Drugs
|July 1, 1995
Summary
Aspirin is the preferred long-term oral antiplatelet therapy for preventing heart attacks. Newer agents like direct thrombin inhibitors and GPIIb/IIIa antagonists show promise for acute conditions but require more research and carry higher bleeding risks.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Cardiovascular diseases often involve acute thromboembolic artery occlusions.
- Endothelial dysfunction can lead to enhanced platelet activity and release of vasoactive mediators.
Purpose of the Study:
- To review the current status of four major classes of antiplatelet compounds.
- To evaluate their efficacy and safety in preventing thromboembolic events.
Main Methods:
- Review of existing literature on aspirin, thienopyridines, direct thrombin inhibitors, and GPIIb/IIIa receptor antagonists.
- Analysis of clinical trial data regarding efficacy and bleeding risk.
Main Results:
- Aspirin is recommended for long-term oral use, particularly for secondary prevention of myocardial infarction.
- Ticlopidine may be superior to aspirin for preventing ischemic stroke and peripheral arterial occlusion.
- Direct thrombin inhibitors and GPIIb/IIIa antagonists are potent for acute syndromes and PTCA but have higher bleeding risks and are for short-term parenteral use.
Conclusions:
- Aspirin remains a cornerstone for long-term oral antiplatelet therapy.
- Further clinical trials are needed for direct thrombin inhibitors and GPIIb/IIIa antagonists.
- Future research focuses on more selective and longer-acting antiplatelet agents.